1. |
Scott IU, Campochiaro PA, Newman NJ, et al. Retinal vascular occlusions[J]. Lancet, 2020, 396(10266): 1927-1940. DOI: 10.1016/S0140-6736(20)31559-2.
|
2. |
赵明威, 苗恒. 视网膜静脉阻塞诊疗重在全病程管理[J]. 中华眼科杂志, 2020, 56(4): 246-249. DOI: 10.3760/cma.j.cn112142-20200207-00052.Zhao MW, Miao H. Whole course management is the key to retinal vein occlusion[J]. Chin J Ophthalmol, 2020, 56(4): 246-249. DOI: 10.3760/cma.j.cn112142-20200207-00052.
|
3. |
Noma H, Yasuda K, Shimura M. Cytokines and pathogenesis of central retinal vein occlusion[J/OL]. J Clin Med, 2020, 9(11): 3457[2020-08-27]. https://pubmed.ncbi.nlm.nih.gov/33121094/. DOI: 10.3390/jcm9113457.
|
4. |
栗怡然, 朱瑞琳, 杨柳. 炎症在视网膜静脉阻塞性黄斑水肿中的作用[J]. 眼科新进展, 2020, 40(1): 90-94. DOI: 10.13389/j.cnki.rao.2020.0023.Li YR, Zhu RL, Yang L. Role of inflammation in macular edema secondary to retinal vein occlusion[J]. Rec Adv Ophthalmol, 2020, 40(1): 90-94. DOI: 10.13389/j.cnki.rao.2020.0023.
|
5. |
李玲娜, 董志军. 视网膜静脉阻塞的研究进展[J]. 国际眼科杂志, 2020, 20(8): 1371-1374. DOI: 10.3980/j.issn.1672-5123.2020.8.16.Li LN, Dong ZJ. Research progress in retinal vein occlusion[J]. Int Eye Sci, 2020, 20(8): 1371-1374. DOI: 10.3980/j.issn.1672-5123.2020.8.16.
|
6. |
Sivaprasad S, Amoaku WM, Hykin P, et al. The royal college of ophthalmologists guidelines on retinal vein occlusions: executive summary[J]. Eye (Lond), 2016, 30(4): 642. DOI: 10.1038/eye.2016.16.
|
7. |
Maggio E, Mete M, Maraone G, et al. Intravitreal injections for macular edema secondary to retinal vein occlusion: long-term functional and anatomic outcomes[J/OL]. J Ophthalmol, 2020, 2020: 7817542[2020-02-13]. https://pubmed.ncbi.nlm.nih.gov/32104597/. DOI: 10.1155/2020/7817542.
|
8. |
Eibenberger K, Schmetterer L, Rezar-Dreindl S, et al. Effects of intravitreal dexamethasone implants on retinal oxygen saturation, vessel diameter, and retrobulbar blood flow velocity in ME secondary to RVO[J]. Invest Ophthalmol Vis Sci, 2017, 58(12): 5022-5029. DOI: 10.1167/iovs.17-22229.
|
9. |
黎晓新, 王宁利, 梁小玲, 等. 地塞米松玻璃体腔植入剂治疗中国患者视网膜静脉阻塞继发黄斑水肿的安全性和有效性: 随机、假注射对照、多中心研究[J]. 中华眼底病杂志, 2018, 34(3): 212-220. DOI: 10.3760/cma.j.issn.1005-1015.2018.03.003.Li XX, Wang NL, Liang XL, et al. Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusionin Chinese patients: randomized, sham-controlled, multicenter study[J]. Chin J Ocul Fundus Dis, 2018, 34(3): 212-220. DOI: 10.3760/cma.j.issn.1005-1015.2018.03.003.
|
10. |
Maier R, Steinbrugger I, Haas A, et al. Role of inflammation-related gene polymorphisms in patients with central retinal vein occlusion[J/OL]. Ophthalmology, 2011, 118(6): 1125-1129[2011-01-26]. https://pubmed.ncbi.nlm.nih.gov/21269700/. DOI: 10.1016/j.ophtha.2010.10.014.
|
11. |
Maturi RK, Chen V, Raghinaru D, et al. A 6-month, subject-masked, randomized controlled study to assess efficacy of dexamethasone as an adjunct to bevacizumab compared with bevacizumab alone in the treatment of patients with macular edema due to central or branch retinal vein occlusion[J/OL]. Clin Ophthalmol, 2014, 8: 1057-1064[2014-06-03]. https://pubmed.ncbi.nlm.nih.gov/24940042/. DOI: 10.2147/OPTH.S60159.
|
12. |
Singer MA, Bell DJ, Woods P, et al. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion[J]. Retina, 2012, 32(7): 1289-1294. DOI: 10.1097/IAE.0b013e318242b838.
|
13. |
Singer MA, Jansen ME, Tyler L, et al. Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: an investigational case series[J/OL]. Clin Ophthalmol, 2016, 11: 31-38[2016-12-19]. https://pubmed.ncbi.nlm.nih.gov/28031700/. DOI: 10.2147/OPTH.S119373.
|
14. |
Iu LP, Zhao P, Yeung IY, et al. Sequential therapy with ranibizumab and dexamethasone intravitreal implant is better than dexamethasone monotherapy for macular oedema due to retinal vein occlusion[J]. Br J Ophthalmol, 2015, 99(2): 210-214. DOI: 10.1136/bjophthalmol-2014-305661.
|
15. |
Manish N, Pravin J, Jainendra R, et al. Outcomes of combination therapy with dexamethasone implant and bevacizumab in macular edema related to vascular occlusions[J]. Taiwan Journal of Ophthalmology, 2014, 4(2): 77-81. DOI: 10.1016/j.tjo.2014.03.008.
|
16. |
邵毅, 张雨晴, 周琼. 视网膜静脉阻塞诊疗规范——2019年欧洲视网膜专家协会指南解读[J]. 眼科新进展, 2020, 40(6): 501-504. DOI: 10.13389/j.cnki.rao.2020.0115.Shao Y, Zhang YQ, Zhou Q. Consensus interpretation on the specification of diagnosis and treatment of retinal vein occlusion by European Society of Retina Specialists in 2019[J]. Rec Adv Ophthalmol, 2020, 40(6): 501-504. DOI: 10.13389/j.cnki.rao.2020.0115.
|
17. |
Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA)[J]. Ophthalmologica, 2019, 242(3): 123-162. DOI: 10.1159/000502041.
|
18. |
Suzuki Y, Nakazawa M, Suzuki K, et al. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion[J]. Jpn J Ophthalmol, 2011, 55(3): 256-263. DOI: 10.1007/s10384-011-0004-8.
|
19. |
邓玉梦, 黄珍, 叶娅, 等. 强反射点与视网膜分支静脉阻塞和中央静脉阻塞患者血脂水平和炎症指标的相关性[J]. 中华眼底病杂志, 2021, 37(2): 115-121. DOI: 10.3760/cma.j.cn511434-20201102-00526.Deng YM, Huang Z, Ye Y, et al. Association between hyper-reflective dots on spectral-domain optical coherence tomography and lipid levels and systemic inflammatory factors in patients with branch or central retinal vein occlusion[J]. Chin J Ocul Fundus Dis, 2021, 37(2): 115-121. DOI: 10.3760/cma.j.cn511434-20201102-00526.
|
20. |
Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results[J]. Ophthalmology, 2011, 118(12): 2453-2460. DOI: 10.1016/j.ophtha.2011.05.014.
|
21. |
Li X, Wang N, Liang X, et al. Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study[J/OL]. Graefe's Arch Clin Exp Ophthalmol, 2018, 256(1): 59-69. DOI: 10.1007/s00417-017-3831-6.
|
22. |
黄江, 邹维杰, 季晓燕, 等. 抗血管内皮生长因子药物联合与不联合视网膜激光光凝治疗视网膜静脉阻塞合并黄斑水肿疗效比较的系统评价[J]. 中华眼底病杂志, 2021, 37(9): 715-722. DOI: 10.3760/cma.j.cn511434-20210622-00334.Huang J, Zou WJ, Ji XY, et al. Comparison of the efficacy of anti-vascular endothelial growth factor drugs with or without retinal laser photocoagulation for macular edema secondary to retinal vein occlusion: a systematic review[J]. Chin J Ocul Fundus Dis, 2021, 37(9): 715-722. DOI: 10.3760/cma.j.cn511434-20210622-00334.
|
23. |
Noma H, Funatsu H, Mimura T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion[J]. Ophthalmology, 2009, 116(1): 87-93. DOI: 10.1016/j.ophtha.2008.09.034.
|
24. |
Yoshimura T, Sonoda KH, Sugahara M, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases[J/OL]. PLoS One, 2009, 4(12): e8158[2009-12-04]. https://pubmed.ncbi.nlm.nih.gov/19997642/. DOI: 10.1371/journal.pone.0008158.
|
25. |
Nicchia GP, Pisani F, Simone L, et al. Glio-vascular modifications caused by Aquaporin-4 deletion in the mouse retina[J]. Exp Eye Res, 2016, 146: 259-268. DOI: 10.1016/j.exer.2016.03.019.
|
26. |
Mayer WJ, Remy M, Wolf A, et al. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema[J]. Ophthalmologica, 2012, 228(2): 110-116. DOI: 10.1159/000338732.
|
27. |
Giuffrè C, Cicinelli MV, Marchese A, et al. Simultaneous intravitreal dexamethasone and aflibercept for refractory macular edema secondary to retinal vein occlusion[J]. Graefe's Arch Clin Exp Ophthalmol, 2020, 258(4): 787-793. DOI: 10.1007/s00417-019-04577-8.
|
28. |
Chin EK, Almeida DRP, Velez G, et al. Ocular hypertension after intravitreal dexamethasone (OZURDEX) sustained-release implant[J]. Retina, 2017, 37(7): 1345-1351. DOI: 10.1097/IAE.0000000000001364.
|
29. |
Choi MY, Kwon JW. Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema[J/OL]. Sci Rep, 2020, 10(1): 13736[2020-08-13]. https://pubmed.ncbi.nlm.nih.gov/32792579/. DOI: 10.1038/s41598-020-70833-1.
|